MUMBAI: A Republican Congresswoman and bitter foe of US presidential candidate Hillary Clinton has dragged Ranbaxy Labs into her latest attack on the Democratic nominee.Congresswoman Marsha Blackburn’s letter, a 71-page report embossed with the seal of the House of Representatives, is titled The Clinton Foundation and the India Success Story: Self-Serving Philanthropy, Watered Down Drugs and Money in sub-Saharan Africa. Its contents appear to be an attempt to conflate Ranbaxy’s regulatory misdemeanors with alleged laxity on the part of the Clinton Health Access Initiative CHAI ), which separated from the Clinton Foundation in 2010. The letter also refers to donations to the foundation made by Ranbaxy and others.A supporter of Donald Trump , Blackburn was once mentioned as a possible running mate for the Republican nominee. A divisive campaign has seen the Trump camp making allegations of corruption, thus far unfounded, against Bill and Hillary Clinton. Sun Pharma didn’t respond to queries.The part related to Ranbaxy, now owned by Sun Pharmaceutical Industries , applies to CHAI’s humanitarian initiatives. The group worked with African governments in Rwanda, Mozambique, Tanzania and South Africa to negotiate price agreements with Ranbaxy contemporaneous with treatment support by the US Agency for International Development USAID ) through PEPFAR (President’s Emergency Plan for AIDS Relief).The organization told ET that it stopped sourcing drugs from Ranbaxy in 2013. “CHAI began working with Ranbaxy in 2003 along with four other pharmaceutical companies to lower the costs of critical AIDS retroviral medications and to increase access to treatment for HIV-positive individuals in low- and lowermiddle-income countries,” CHAI told ET in an email. “CHAI works with many pharmaceutical companies that supply AIDS retroviral medications.”The drugs used were subject to rigorous standards. “Medications received from Ranbaxy, as with all medications CHAI receives and helps distribute, were approved by stringent regulatory agencies such as the World Health Organization (WHO) and the US Food and Drug Administration ( FDA ),” it said.After the FDA’s 2008 import alert, CHAI stopped sourcing drugs from Ranbaxy with the exception of two small batch medications, of which Ranbaxy was the sole supplier